A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

This is an open-label, multicenter and observational study in China, which is designed to record the data of RA & AS patients within 52 weeks after rheumatologists decided to prescribe etanercept, and evaluate the safety and efficacy of the treatment. All eligible subjects agreed to be recruited in the study and can withdraw anytime if they choose so.

Patients with RA or AS are typically managed by rheumatologists. As this study seeks to record the data of RA & AS patient in etanercept and evaluate the safety and efficacy of the treatment, patients will be recruited from Rheumatic department. Rheumatologist will be asked to build up the database for RA & AS patient surveillance prospectively in outpatient dept, which benefits for the patient treatment outcomes evaluation and clinical management.

• Rheumatoid Arthritis
• Ankylosing Spondylitis

Inclusion Criteria:

• Subject has a confirmed diagnosis of rheumatoid arthritis or ankylosing spondylitis.
• Subject has accepted physician's prescription of etanercept in rheumatology department.
• Subject agreed to be enrolled in the observational study and sign the ICD.
• Subject is?18 years of age at the time of consent.
• Subject is willing and able to understand and complete questionnaires

Exclusion Criteria:

• Presence of active or suspected latent infection including HIV, or any underlying disease, including open cutaneous ulcers that could predispose the subject to infections.
• Immunodeficiency syndromes including Felty syndrome or large granular lymphocyte syndrome.
• Active tuberculosis (TB) or a history of TB, or findings consistent with previous exposure to TB on a chest x-ray (CXR). Investigators must follow China's guidelines for appropriate screening and treatment of TB.
• History of hypersensitivity to any of the ingredients in either preparation.